Chronic lymphocytic leukemia natural history, complications and prognosis
Chronic lymphocytic leukemia Microchapters |
Differentiating Chronic lymphocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Chronic lymphocytic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Chronic lymphocytic leukemia natural history, complications and prognosis |
FDA on Chronic lymphocytic leukemia natural history, complications and prognosis |
CDC on Chronic lymphocytic leukemia natural history, complications and prognosis |
Chronic lymphocytic leukemia natural history, complications and prognosis in the news |
Blogs on Chronic lymphocytic leukemia natural history, complications and prognosis |
Directions to Hospitals Treating Chronic lymphocytic leukemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Most patients with chronic lymphocytic leukemia are initially asymptomatic. If left untreated, patients with chronic lymphocytic leukemia may progress to develop weight loss, fever, and lymph nodes swelling. Common complications of chronic lymphocytic leukemia include immunodeficiency, warm autoimmune hemolytic anemia, and Richter's transformation. Prognosis is generally good, and the 5-year survival rate of patients with chronic lymphocytic leukemia is 81.7%.
Natural History, Complications and Prognosis
Natural History
- Most patients with chronic lymphocytic leukemia are initially asymptomatic.
- If left untreated, patients with chronic lymphocytic leukemia may progress to develop weight loss, fever, and lymph nodes swelling.
Complications
Prognosis
- Prognosis is generally good, and the 5-year survival rate of patients with chronic lymphocytic leukemia is 81.7%.[5]
- Common prognostic factors for chronic lymphocytic leukemia patients include age, tumor stage, and the presence of certain genetic mutations.[6]
- The table below lists prognostic factors for chronic lymphocytic leukemia patients:[7][8][1]
Prognostic Factor | Description |
---|---|
Age | |
Gender | |
Performance status |
|
Stage |
|
Lymphocyte doubling time |
|
Genetic mutations |
|
Prolymphocytes percent |
|
Histological analysis |
|
Lactate dehydrogenase (LDH) level | |
β2-microglobulin level |
|
Lymphocyte surface markers |
|
Immunoglobulin (Ig)VH gene | |
Membrane-bound proteins |
|
References
- ↑ 1.0 1.1 Nabhan C, Rosen ST (2014). "Chronic lymphocytic leukemia: a clinical review". JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
- ↑ Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G (May 2000). "Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features". Blood. 95 (9): 2786–92. PMID 10779422.
- ↑ Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ (October 1993). "Richter's syndrome: a report on 39 patients". J. Clin. Oncol. 11 (10): 1985–9. doi:10.1200/JCO.1993.11.10.1985. PMID 8410123.
- ↑ Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, Ambrosetti A, Madeo D, Pizzolo G, Rodeghiero F (February 2008). "Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia". Blood. 111 (3): 1110–6. doi:10.1182/blood-2007-09-111492. PMID 17986663.
- ↑ SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. National Cancer Institute (2015) http://seer.cancer.gov/statfacts/html/clyl.html Accessed on October, 12 2015
- ↑ Chen C, Puvvada S (February 2016). "Prognostic Factors for Chronic Lymphocytic Leukemia". Curr Hematol Malig Rep. 11 (1): 37–42. doi:10.1007/s11899-015-0294-x. PMID 26748932.
- ↑ Shanafelt TD, Geyer SM, Kay NE (February 2004). "Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL". Blood. 103 (4): 1202–10. doi:10.1182/blood-2003-07-2281. PMID 14576043.
- ↑ Chen C, Puvvada S (February 2016). "Prognostic Factors for Chronic Lymphocytic Leukemia". Curr Hematol Malig Rep. 11 (1): 37–42. doi:10.1007/s11899-015-0294-x. PMID 26748932.